Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Predictive Oncology Inc (POAI)

Predictive Oncology Inc (POAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,184
  • Shares Outstanding, K 4,102
  • Annual Sales, $ 1,780 K
  • Annual Income, $ -13,980 K
  • 60-Month Beta 1.16
  • Price/Sales 2.40
  • Price/Cash Flow N/A
  • Price/Book 1.04
Trade POAI with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8940 +12.98%
on 06/21/24
1.5100 -33.11%
on 06/04/24
-0.4400 (-30.34%)
since 06/03/24
3-Month
0.8940 +12.98%
on 06/21/24
2.5900 -61.00%
on 05/28/24
-0.9500 (-48.47%)
since 04/03/24
52-Week
0.8940 +12.98%
on 06/21/24
7.1200 -85.81%
on 07/18/23
-3.8350 (-79.15%)
since 07/03/23

Most Recent Stories

More News
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
AGLE : 12.01 (+8.79%)
TALS : 27.20 (-0.73%)
POAI : 1.0100 (-0.98%)
MRTX : 58.70 (-0.17%)
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

/PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
AGLE : 12.01 (+8.79%)
TALS : 27.20 (-0.73%)
POAI : 1.0100 (-0.98%)
MRTX : 58.70 (-0.17%)
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm

EAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business...

POAI : 1.0100 (-0.98%)
Predictive Oncology Announces Closing of $7.2 Million Registered Direct Offerings

EAGAN, Minn., May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven...

POAI : 1.0100 (-0.98%)
Predictive Oncology Announces $7.2 Million Registered Direct Offerings

EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven...

POAI : 1.0100 (-0.98%)
Predictive Oncology Reports First Quarter Financial Results

EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the...

POAI : 1.0100 (-0.98%)
Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology

EAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director...

POAI : 1.0100 (-0.98%)
Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update

EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial...

POAI : 1.0100 (-0.98%)
Predictive Oncology validates Discovery 21 proof-of-concept campaign

Predictive Oncology's Discovery 21 campaign evaluated the ability of its PeDAL® platform to make high-confidence predictions in ovarian tumor samples....

POAI : 1.0100 (-0.98%)
Predictive Oncology set to market AI drug discovery platform

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI)...

POAI : 1.0100 (-0.98%)

Business Summary

Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS.

See More

Key Turning Points

3rd Resistance Point 1.1167
2nd Resistance Point 1.0833
1st Resistance Point 1.0467
Last Price 1.0100
1st Support Level 0.9767
2nd Support Level 0.9433
3rd Support Level 0.9067

See More

52-Week High 7.1200
Fibonacci 61.8% 4.7417
Fibonacci 50% 4.0070
Fibonacci 38.2% 3.2723
Last Price 1.0100
52-Week Low 0.8940

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar